Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
QNCXQuince TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Sirolimus/Rapamycin (LAM-001) (mTOR Inhibitor) in Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD). The expected timing is based on the latest available company guidance and may change.
05/18/26:- Ph2a improved 6MWD/PVR in PH-ILD. Ph2b to start Mid-2026; topline Q1 2028. 08/14/26:- Phase 2b PH-ILD trial initiated and subjects are screening. Topline data is expected in Q1 2028.
Verification
Confirm timing and program details against the company announcement or filing.